JP2018502838A5 - - Google Patents

Download PDF

Info

Publication number
JP2018502838A5
JP2018502838A5 JP2017530094A JP2017530094A JP2018502838A5 JP 2018502838 A5 JP2018502838 A5 JP 2018502838A5 JP 2017530094 A JP2017530094 A JP 2017530094A JP 2017530094 A JP2017530094 A JP 2017530094A JP 2018502838 A5 JP2018502838 A5 JP 2018502838A5
Authority
JP
Japan
Prior art keywords
composition
camkk1
tissue
organ
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2017530094A
Other languages
English (en)
Japanese (ja)
Other versions
JP6893873B2 (ja
JP2018502838A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/063118 external-priority patent/WO2016089826A1/en
Publication of JP2018502838A publication Critical patent/JP2018502838A/ja
Publication of JP2018502838A5 publication Critical patent/JP2018502838A5/ja
Priority to JP2021032502A priority Critical patent/JP2021098717A/ja
Application granted granted Critical
Publication of JP6893873B2 publication Critical patent/JP6893873B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2017530094A 2014-12-01 2015-12-01 新規の再生治療剤としてのｃａｍｋｋ１ Active JP6893873B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021032502A JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462086026P 2014-12-01 2014-12-01
US62/086,026 2014-12-01
PCT/US2015/063118 WO2016089826A1 (en) 2014-12-01 2015-12-01 Camkk1 as a novel regenerative therapeutic

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021032502A Division JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Publications (3)

Publication Number Publication Date
JP2018502838A JP2018502838A (ja) 2018-02-01
JP2018502838A5 true JP2018502838A5 (cg-RX-API-DMAC7.html) 2019-01-17
JP6893873B2 JP6893873B2 (ja) 2021-06-23

Family

ID=56092307

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017530094A Active JP6893873B2 (ja) 2014-12-01 2015-12-01 新規の再生治療剤としてのｃａｍｋｋ１
JP2021032502A Pending JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021032502A Pending JP2021098717A (ja) 2014-12-01 2021-03-02 新規の再生治療剤としてのｃａｍｋｋ１

Country Status (12)

Country Link
US (2) US11273208B2 (cg-RX-API-DMAC7.html)
EP (2) EP3940068A1 (cg-RX-API-DMAC7.html)
JP (2) JP6893873B2 (cg-RX-API-DMAC7.html)
KR (3) KR102236843B1 (cg-RX-API-DMAC7.html)
AU (1) AU2015355188B2 (cg-RX-API-DMAC7.html)
CA (1) CA3007055C (cg-RX-API-DMAC7.html)
CL (1) CL2017001390A1 (cg-RX-API-DMAC7.html)
CR (1) CR20170301A (cg-RX-API-DMAC7.html)
IL (2) IL252612B (cg-RX-API-DMAC7.html)
RU (1) RU2017122817A (cg-RX-API-DMAC7.html)
UA (1) UA124450C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016089826A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016089826A1 (en) 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
EP3781182A4 (en) 2018-04-18 2021-11-17 Summa Health COMPOSITIONS AND METHODS OF TREATMENT OF ISCHEMIA AND CARDIOMYOPATHIA

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6426206B1 (en) * 2000-11-13 2002-07-30 Pe Corporation (Ny) Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof
WO2002072115A2 (en) 2001-03-09 2002-09-19 Board Of Regents, The University Of Texas System Vectors, compositions and methods for treating a vascular disorder
US7776564B2 (en) 2004-04-30 2010-08-17 Five Prime Therapeutics, Inc. Stromal cell-derived factor-1 polypeptides, polynucleotides, modulators thereof and methods of use
US7764995B2 (en) * 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US8173118B2 (en) * 2004-07-30 2012-05-08 Mayo Foundation For Medical Education And Research Compositions consisting essentially of TGF-β, BMP-2 FGF-4, leukemia inhibitory factor, IGF-1, IL-6 and H-α-thrombin
CN101103101B (zh) 2004-09-24 2012-10-10 成血管细胞系统公司 增强间充质前体细胞（mpc）的增生和/或存活的方法
US20090246179A1 (en) 2008-02-11 2009-10-01 The Cleveland Clinic Foundation Method of treating myocardial injury
EP2687219A1 (en) * 2012-07-18 2014-01-22 Universität Duisburg-Essen Use of preparations comprising exosomes derived from mesenchymal stem cells (MSCs) in the prevention and therapy of inflammatory conditions
EP3039124A1 (en) * 2013-08-29 2016-07-06 Stempeutics Research Private Limited Stromal cells derived conditioned medium, method of obtaining said conditioned medium compositions, formulations and applications thereof
WO2016089826A1 (en) * 2014-12-01 2016-06-09 Summa Health Camkk1 as a novel regenerative therapeutic
HK1246180A1 (zh) 2014-12-31 2018-09-07 Celgene Corporation 使用自然杀伤细胞治疗血液病症、实体瘤或感染性疾病的方法

Similar Documents

Publication Publication Date Title
Hu et al. Islet‑1 Mesenchymal Stem Cells-Derived Exosome-Incorporated Angiogenin‑1 Hydrogel for Enhanced Acute Myocardial Infarction Therapy
Dai et al. Chronic AMD3100 antagonism of SDF-1α–CXCR4 exacerbates cardiac dysfunction and remodeling after myocardial infarction
Takahashi Role of the SDF-1/CXCR4 system in myocardial infarction
Hong et al. Does remote ischaemic preconditioning with postconditioning improve clinical outcomes of patients undergoing cardiac surgery? Remote Ischaemic Preconditioning with Postconditioning Outcome Trial
Tarui et al. Transcoronary infusion of cardiac progenitor cells in hypoplastic left heart syndrome: Three-year follow-up of the Transcoronary Infusion of Cardiac Progenitor Cells in Patients With Single-Ventricle Physiology (TICAP) trial
Kim et al. Human peripheral blood-derived CD31+ cells have robust angiogenic and vasculogenic properties and are effective for treating ischemic vascular disease
Tang et al. Improved graft mesenchymal stem cell survival in ischemic heart with a hypoxia-regulated heme oxygenase-1 vector
Xu et al. Circulating mesenchymal stem cells and their clinical implications
Cabrera-Benitez et al. Mechanical ventilation–associated lung fibrosis in acute respiratory distress syndrome a significant contributor to poor outcome
ES2401608T3 (es) Blastocitos CD34 mesenquimales para uso en terapia génica de diabetes
JP2016515533A5 (cg-RX-API-DMAC7.html)
Chen et al. Hyaluronan enhances bone marrow cell therapy for myocardial repair after infarction
Bagno et al. Sustained IGF-1 secretion by adipose-derived stem cells improves infarcted heart function
JP2009545310A5 (cg-RX-API-DMAC7.html)
EP2637702A1 (en) Methods, compositions, cells, and kits for treating ischemic injury
Zhao et al. Mesenchymal stem cell biodistribution, migration, and homing in vivo
Wen et al. SDF-1α and CXCR4 as therapeutic targets in cardiovascular disease
Liang et al. Hydrogels for the treatment of myocardial infarction: design and therapeutic strategies
Fidelis-de-Oliveira et al. Soluble factors from multipotent mesenchymal stromal cells have antinecrotic effect on cardiomyocytes in vitro and improve cardiac function in infarcted rat hearts
Pagano et al. On the road to regeneration:“tools” and “routes” towards efficient cardiac cell therapy for ischemic cardiomyopathy
Naim et al. Gene therapy for heart failure: where do we stand?
Kloc et al. Reciprocal interactions between mesenchymal stem cells and macrophages
RU2017122817A (ru) Camkk1 в качестве нового регенеративного терапевтического средства
Guan et al. Cardiac resident progenitor cells: evidence and functional significance
Chen et al. Ultrasound-targeted microbubble destruction enhances delayed BMC delivery and attenuates post-infarction cardiac remodelling by inducing engraftment signals